Vaxart (VXRT) is a leading Biotechnology business with stocks listed in the USA. It opened the day at US$8.45, after a previous close of US$8.85. During the day the price has varied from a low of US$7.81 to a high of US$8.85. The latest price was US$8 (25-minute delay). Vaxart (VXRT) is listed on the NASDAQ and employs 14 staff. All prices are listed in US Dollars.
How to buy shares in Vaxart
Compare share trading platforms. To buy shares in a US company from Australia you’ll need to find a trading platform that offers access to US stock markets. If you’re just starting out, look for a platform with low brokerage and foreign exchange fees.
Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
Search for Vaxart. Find the share by name or ticker symbol: VXRT. Research its history to confirm it's a solid investment against your financial goals.
Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Vaxart reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
Decide on how many to buy. At today's price of US$8, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Vaxart, depending on your broker.
Check in on your investment. Congratulations, you own a part of Vaxart. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Important: Share trading carries risk of capital loss.
Compare share trading platforms
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
This is not a recommendation, it represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Vaxart company summary
Information last updated 2020-06-26.
Vaxart (VXRT) is a leading Biotechnology business based in the USA. Vaxart (VXRT) is listed on the NASDAQ and employs 14 staff.
Profile
Industry
Biotechnology
Currency symbol
$
Code
VXRT
Country name
USA
Type
Common Stock
Country ISO
US
Name
Vaxart, Inc
ISIN
US92243A2006
Exchange
NASDAQ
CUSIP
053761102
Currency code
USD
Sector
Healthcare
Currency name
US Dollar
Full-time employees
14
Detailed company information
Vaxart, Inc., a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus. It is also developing therapeutic immune-oncology vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.
Frequently asked questions
Latest data suggests 14 work at Vaxart.
Vaxart's fiscal year ends in December
Vaxart's address is: 395 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Vaxart's ISIN is: US92243A2006
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
The Galaxy Tab S6 Lite is a worthy competitor to Apple's entry-level iPad, but Android's ongoing issues with tablet apps still leave it lagging behind Apple's efforts.
How likely would you be to recommend finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
Important information about this website
finder.com.au is one of Australia's leading comparison websites. We compare from a wide set of banks, insurers and product issuers. We value our editorial independence and follow editorial guidelines.
finder.com.au has access to track details from the product issuers listed on our sites. Although we provide information on the products offered by a wide range of issuers, we don't cover every available product or service.
Please note that the information published on our site should not be construed as personal advice and does not consider your personal needs and circumstances. While our site will provide you with factual information and general advice to help you make better decisions, it isn't a substitute for professional advice. You should consider whether the products or services featured on our site are appropriate for your needs. If you're unsure about anything, seek professional advice before you apply for any product or commit to any plan.
Products marked as 'Promoted' or 'Advertisement' are prominently displayed either as a result of a commercial advertising arrangement or to highlight a particular product, provider or feature. Finder may receive remuneration from the Provider if you click on the related link, purchase or enquire about the product. Finder's decision to show a 'promoted' product is neither a recommendation that the product is appropriate for you nor an indication that the product is the best in its category. We encourage you to use the tools and information we provide to compare your options.
Where our site links to particular products or displays 'Go to site' buttons, we may receive a commission, referral fee or payment when you click on those buttons or apply for a product. You can learn more about how we make money here.
When products are grouped in a table or list, the order in which they are initially sorted may be influenced by a range of factors including price, fees and discounts; commercial partnerships; product features; and brand popularity. We provide tools so you can sort and filter these lists to highlight features that matter to you.
We try to take an open and transparent approach and provide a broad-based comparison service. However, you should be aware that while we are an independently owned service, our comparison service does not include all providers or all products available in the market.
Some product issuers may provide products or offer services through multiple brands, associated companies or different labelling arrangements. This can make it difficult for consumers to compare alternatives or identify the companies behind the products. However, we aim to provide information to enable consumers to understand these issues.
Providing or obtaining an estimated insurance quote through us does not guarantee you can get the insurance. Acceptance by insurance companies is based on things like occupation, health and lifestyle. By providing you with the ability to apply for a credit card or loan, we are not guaranteeing that your application will be approved. Your application for credit products is subject to the Provider's terms and conditions as well as their application and lending criteria.
Please read our website terms of use and privacy policy for more information about our services and our approach to privacy.
